CoChat

TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency

Open access

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

To study whether TGF-β1/IL-11/MEK/ERK (TIME) signaling mediates senescence-associated pulmonary fibrosis (SAPF) in Bmi-1-deficient (Bmi-1−/−) mice and determines the major downstream mediator of Bmi-1 and crosstalk between p16 INK4a and reactive oxygen species that regulates SAPF, phenotypes were compared among 7-week-old p16INK4a and Bmi-1 double-knockout, N-acetylcysteine (NAC)-treated Bmi-1−/−, Bmi-1−/−, and wild-type mice. Pulmonary fibroblasts and alveolar type II epithelial (AT2) cells were used for experiments. Human pulmonary tissues were tested for type Ι collagen, α-smooth muscle actin (α-SMA), p16 INK4a, p53, p21, and TIME signaling by using enzyme-linked immunosorbent assay (ELISA). Our results demonstrated that Bmi-1 deficiency resulted in a shortened lifespan, ventilatory resistance, poor ventilatory compliance, and SAPF, including cell senescence, DNA damage, a senescence-associated secretory phenotype and collagen overdeposition that was mediated by the upregulation of TIME signaling. The signaling stimulated cell senescence, senescence-related secretion of TGF-β1 and IL-11 and production of collagen 1 by pulmonary fibroblasts and the epithelial-to-mesenchymal transition of AT2 cells. These processes were inhibited by anti-IL-11 or the MEK inhibitor PD98059. NAC treatment prolonged the lifespan and ameliorated pulmonary dysfunction and SAPF by downregulating TIME signaling more than p16INK4a deletion by inhibiting oxidative stress and DNA damage and promoting ubiquitin-proteasome degradation of p16 INK4a and p53. Cytoplasmic p16 INK4a accumulation upregulated MEK/ERK signaling by inhibiting the translocation of pERK1/2 (Thr202/Tyr204) from the cytoplasm to the nucleus in senescent fibroblasts. The accumulation of collagen 1 and α-SMA in human lungs accompanied by cell senescence may be mediated by TIME signaling. Thus, this signaling in aging fibroblasts or AT2 cells could be a therapeutic target for preventing SAPF.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s12276-019-0371-7

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 NAC treatment improved premature senescence and pulmonary dysfunction in Bmi-1−/− mice better than in Bmi-1−/−p16−/− mice. a Representative appearances of 7-week-old WT, Bmi-1−/−, Bmi-1−/−p16−/−, and NAC-treated Bmi-1−/− (Bmi-1−/− + NAC) mice. b Percent survival of the mice. Pulmonary function was detected by the Buxco measurement system and FinePointe analysis for c peak inspiratory flow, d frequency, e tidal volume, f lung resistance, g dynamic compliance, h minute volume, i static compliance, and j elastance. Six mice per group were used for experiments. Values are the means ± SEM of six determinations per group. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01 compared with the Bmi-1−/− group; &P < 0.05 compared with the Bmi-1−/−p16−/− group.
Fig. 1 NAC treatment improved premature senescence and pulmonary dysfunction in Bmi-1−/− mice better than in Bmi-1−/−p16−/− mice. a Representative appearances of 7-week-old WT, Bmi-1−/−, Bmi-1−/−p16−/−, and NAC-treated Bmi-1−/− (Bmi-1−/− + NAC) mice. b Percent survival of the mice. Pulmonary function was detected by the Buxco measurement system and FinePointe analysis for c peak inspiratory flow, d frequency, e tidal volume, f lung resistance, g dynamic compliance, h minute volume, i static compliance, and j elastance. Six mice per group were used for experiments. Values are the means ± SEM of six determinations per group. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01 compared with the Bmi-1−/− group; &P < 0.05 compared with the Bmi-1−/−p16−/− group.CC BY · PubMed Central
Fig. 2 NAC treatment improved pulmonary cell senescence, DNA damage, and SASP in Bmi-1−/− mice more than in Bmi-1−/−p16−/− mice. a Representative micrographs of paraffin-embedded pulmonary sections stained for senescence-associated β-galactosidase (SA-β-gal), stained immunohistochemically for p53, 8-hydroxyguanosine (8-OHdG), IL-1β, IL-6, and TNF-α, and stained immunofluorescently for CD3 and F4/80. SA-β-gal-, p53-, 8-OHdG-, CD3-, or F4/80-positive cells are indicated by arrows. b Percentage of cells positive for SA-β-gal, p53, 8-OHdG, CD3, F4/80, IL-1β, IL-6, and TNF-α or with positive area relative to the total cells or area. c Bmi-1, p16, IL-1a, IL-1β, IL-6, and TNF-α mRNA levels in lungs by real-time RT-PCR, calculated as the ratio to β-actin mRNA and expressed relative to that of WT. d Western blots of pulmonary extracts showing p16, p19, p53, p21, and 8-OHdG. β-actin was used as the loading control. e Protein levels relative to β-actin were assessed by densitometric analysis. Six mice per group were used for experiments. Values are the mean ± SEM from six determinations per group. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01, &&&P < 0.001 compared with the Bmi-1−/−p16−/− group.
Fig. 2 NAC treatment improved pulmonary cell senescence, DNA damage, and SASP in Bmi-1−/− mice more than in Bmi-1−/−p16−/− mice. a Representative micrographs of paraffin-embedded pulmonary sections stained for senescence-associated β-galactosidase (SA-β-gal), stained immunohistochemically for p53, 8-hydroxyguanosine (8-OHdG), IL-1β, IL-6, and TNF-α, and stained immunofluorescently for CD3 and F4/80. SA-β-gal-, p53-, 8-OHdG-, CD3-, or F4/80-positive cells are indicated by arrows. b Percentage of cells positive for SA-β-gal, p53, 8-OHdG, CD3, F4/80, IL-1β, IL-6, and TNF-α or with positive area relative to the total cells or area. c Bmi-1, p16, IL-1a, IL-1β, IL-6, and TNF-α mRNA levels in lungs by real-time RT-PCR, calculated as the ratio to β-actin mRNA and expressed relative to that of WT. d Western blots of pulmonary extracts showing p16, p19, p53, p21, and 8-OHdG. β-actin was used as the loading control. e Protein levels relative to β-actin were assessed by densitometric analysis. Six mice per group were used for experiments. Values are the mean ± SEM from six determinations per group. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01, &&&P < 0.001 compared with the Bmi-1−/−p16−/− group.CC BY · PubMed Central
Fig. 3 NAC treatment improved pulmonary fibrosis in Bmi-1−/− mice more than in Bmi-1−/−p16−/− mice. a Representative micrographs of paraffin-embedded pulmonary sections stained histochemically for Masson’s trichrome (Masson), immunohistochemically for α-smooth muscle actin (α-SMA), type Ι collagen (collagen 1), fibronectin, TGF-β1 and IL-11, and immunofluorescently for IL-11 receptor α1 (Rα1) and SFTPC, with DAPI staining the nuclei. b Percentage of cells positive for Masson, α-SMA, collagen 1, fibronectin, TGF-β1, IL-11, IL-11Rα1, or SFTPC or positive areas relative to the total cells or areas. c Col1a1, Col1a2, ACTA2, plasminogen activator inhibitor-1 (PAI-1), TGF-β1, matrix metalloproteinases (MMP9), MMP12, IL-11 and IL-11Rα1 and SFTPC mRNA levels in lungs by real-time RT-PCR, calculated as the ratio to β-actin mRNA and expressed relative to that of WT. Six mice per group were used for experiments. Values are the mean ± SEM from six determinations per group. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01 compared with the Bmi-1−/−p16−/− group.
Fig. 3 NAC treatment improved pulmonary fibrosis in Bmi-1−/− mice more than in Bmi-1−/−p16−/− mice. a Representative micrographs of paraffin-embedded pulmonary sections stained histochemically for Masson’s trichrome (Masson), immunohistochemically for α-smooth muscle actin (α-SMA), type Ι collagen (collagen 1), fibronectin, TGF-β1 and IL-11, and immunofluorescently for IL-11 receptor α1 (Rα1) and SFTPC, with DAPI staining the nuclei. b Percentage of cells positive for Masson, α-SMA, collagen 1, fibronectin, TGF-β1, IL-11, IL-11Rα1, or SFTPC or positive areas relative to the total cells or areas. c Col1a1, Col1a2, ACTA2, plasminogen activator inhibitor-1 (PAI-1), TGF-β1, matrix metalloproteinases (MMP9), MMP12, IL-11 and IL-11Rα1 and SFTPC mRNA levels in lungs by real-time RT-PCR, calculated as the ratio to β-actin mRNA and expressed relative to that of WT. Six mice per group were used for experiments. Values are the mean ± SEM from six determinations per group. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01 compared with the Bmi-1−/−p16−/− group.CC BY · PubMed Central
Fig. 4 NAC treatment inhibited TIME signaling in Bmi-1−/− mice more than in Bmi-1−/−p16−/− mice. Western blots of pulmonary extracts showing a SFTPC, collagen 1, α-SMA, mature TGF-β1, TGF-βRII, Smad2, pSmad2 (Ser465/467), pSmad2/3 (Ser423/425); b IL-11, IL-11Rα1, MEK1/2, pMEK1/2(Ser217/221), ERK1/2, pERK1/2(Thr202/Tyr204), elF4E, p-elF4E(Ser209), RSK, and p-RSK(Ser380). c, d Protein expression relative to β-actin (graph a) was assessed by densitometric analysis. Six mice per group were used for experiments. Values are the means ± SEM of six determinations. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01 compared with the Bmi-1−/−p16−/− group. e Pulmonary fibroblasts from 7-week-old WT mice treated with TGF-β1 (5 ng/ml, 48 h), TGF-β1 (5 ng/ml, 48 h) and anti-IL-11 antibody (2 μg/ml, 48 h), IL-11 (5 ng/ml, 48 h), or IL-11 (5 ng/ml, 48 h) and the MEK inhibitor (PD98059) (10 μm, 48 h). Representative micrographs immunofluorescently labeled for IL-11 and vimentin, with DAPI staining the nuclei. f Percentage of IL-11-positive areas relative to the total. g Western blots showing p16, IL-11, and collagen 1. β-actin was used as the loading control. h Protein expression relative to β-actin was assessed by densitometric analysis. Six biological replicates were used per experiment. Values are the means ± SEM of six determinations. ^P < 0.05, ^^P < 0.01, ^^^P < 0.001 compared with the vehicle group; +P < 0.05, ++P < 0.01 compared with the TGF-β1 group; @P < 0.05, @@P < 0.01 compared with the TGF-β1 and anti-IL-11 group; −−P < 0.01 compared with the IL-11 group.
Fig. 4 NAC treatment inhibited TIME signaling in Bmi-1−/− mice more than in Bmi-1−/−p16−/− mice. Western blots of pulmonary extracts showing a SFTPC, collagen 1, α-SMA, mature TGF-β1, TGF-βRII, Smad2, pSmad2 (Ser465/467), pSmad2/3 (Ser423/425); b IL-11, IL-11Rα1, MEK1/2, pMEK1/2(Ser217/221), ERK1/2, pERK1/2(Thr202/Tyr204), elF4E, p-elF4E(Ser209), RSK, and p-RSK(Ser380). c, d Protein expression relative to β-actin (graph a) was assessed by densitometric analysis. Six mice per group were used for experiments. Values are the means ± SEM of six determinations. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01 compared with the Bmi-1−/−p16−/− group. e Pulmonary fibroblasts from 7-week-old WT mice treated with TGF-β1 (5 ng/ml, 48 h), TGF-β1 (5 ng/ml, 48 h) and anti-IL-11 antibody (2 μg/ml, 48 h), IL-11 (5 ng/ml, 48 h), or IL-11 (5 ng/ml, 48 h) and the MEK inhibitor (PD98059) (10 μm, 48 h). Representative micrographs immunofluorescently labeled for IL-11 and vimentin, with DAPI staining the nuclei. f Percentage of IL-11-positive areas relative to the total. g Western blots showing p16, IL-11, and collagen 1. β-actin was used as the loading control. h Protein expression relative to β-actin was assessed by densitometric analysis. Six biological replicates were used per experiment. Values are the means ± SEM of six determinations. ^P < 0.05, ^^P < 0.01, ^^^P < 0.001 compared with the vehicle group; +P < 0.05, ++P < 0.01 compared with the TGF-β1 group; @P < 0.05, @@P < 0.01 compared with the TGF-β1 and anti-IL-11 group; −−P < 0.01 compared with the IL-11 group.CC BY · PubMed Central
Fig. 5 NAC treatment inhibited cell senescence and TIME signaling in Bmi-1−/− more than in Bmi-1−/−p16−/− pulmonary fibroblasts. Pulmonary fibroblasts from 7-week-old WT, Bmi-1−/−, Bmi-1−/−p16−/−, and NAC-treated Bmi-1−/− (Bmi-1−/− + NAC) mice. a Representative micrographs of cells stained cytochemically for SA-β-gal. b Percentage of SA-β-gal-positive areas relative to the total areas. c Third-passage fibroblast proliferation was determined by CCK-8 assays and spectrophotometry at 450 nm. Cell number was determined at the indicated hours relative to the cell number at hour 0. d TGF-β1 and IL-11 concentrations were detected in conditioned medium (CM) by ELISA and assessed by densitometric analysis relative to that of WT CM. e, f Western blots for mature TGF-β1, IL-11, p19, p53, p21, α-SMA, p16, pERK1/2 (Thr202/Tyr204), and ERK1/2. β-actin was used as the loading control. g Protein expression relative to β-actin was assessed by densitometric analysis. h Representative micrographs showing immunofluorescence for IL-11 and p53, with DAPI staining the nuclei. i Percentage of IL-11-positive areas (in p53-positive cells) or p53-positive areas relative to the total area assessed. Six biological replicates were used per experiment. Values are the means ± SEM of six determinations. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01 compared with the Bmi-1−/−p16−/− group. j Western blots of pulmonary fibroblasts from the NAC (1 mm, 48 h)-treated Bmi-1−/− (Bmi-1−/− + NAC) group and the NAC (1 mm, 48 h) & MG132 (5 μm, 48 h)-treated Bmi-1−/− (Bmi-1−/− + NAC + MG132) group. k Protein expression relative to β-actin was assessed by densitometric analysis. Six biological replicates were used per experiment. Values are the means ± SEM of six determinations. **P < 0.01, ***P < 0.001 compared with the NAC-treated Bmi-1−/− group.
Fig. 5 NAC treatment inhibited cell senescence and TIME signaling in Bmi-1−/− more than in Bmi-1−/−p16−/− pulmonary fibroblasts. Pulmonary fibroblasts from 7-week-old WT, Bmi-1−/−, Bmi-1−/−p16−/−, and NAC-treated Bmi-1−/− (Bmi-1−/− + NAC) mice. a Representative micrographs of cells stained cytochemically for SA-β-gal. b Percentage of SA-β-gal-positive areas relative to the total areas. c Third-passage fibroblast proliferation was determined by CCK-8 assays and spectrophotometry at 450 nm. Cell number was determined at the indicated hours relative to the cell number at hour 0. d TGF-β1 and IL-11 concentrations were detected in conditioned medium (CM) by ELISA and assessed by densitometric analysis relative to that of WT CM. e, f Western blots for mature TGF-β1, IL-11, p19, p53, p21, α-SMA, p16, pERK1/2 (Thr202/Tyr204), and ERK1/2. β-actin was used as the loading control. g Protein expression relative to β-actin was assessed by densitometric analysis. h Representative micrographs showing immunofluorescence for IL-11 and p53, with DAPI staining the nuclei. i Percentage of IL-11-positive areas (in p53-positive cells) or p53-positive areas relative to the total area assessed. Six biological replicates were used per experiment. Values are the means ± SEM of six determinations. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01 compared with the Bmi-1−/−p16−/− group. j Western blots of pulmonary fibroblasts from the NAC (1 mm, 48 h)-treated Bmi-1−/− (Bmi-1−/− + NAC) group and the NAC (1 mm, 48 h) & MG132 (5 μm, 48 h)-treated Bmi-1−/− (Bmi-1−/− + NAC + MG132) group. k Protein expression relative to β-actin was assessed by densitometric analysis. Six biological replicates were used per experiment. Values are the means ± SEM of six determinations. **P < 0.01, ***P < 0.001 compared with the NAC-treated Bmi-1−/− group.CC BY · PubMed Central
Fig. 6 NAC treatment inhibited cell senescence, and TIME signaling mediated the EMT in Bmi-1−/− cells more than in Bmi-1−/−p16−/− AT2 cells. Pulmonary AT2 cells from 7-week-old WT, Bmi-1−/−, Bmi-1−/−p16−/−, and NAC-treated Bmi-1−/− (Bmi-1−/− + NAC) mice. a Representative micrographs of cells stained cytochemically for SA-β-gal. b Percentage of SA-β-gal-positive areas relative to the total. c Second-passage AT2 cell proliferation were determined by CCK-8 assays, and spectrophotometry at 450 nm. Cell number was determined at the indicated hours relative to the cell number at hour 0. d Western blots for SFTPC, α-SMA, pERK1/2 (Thr202/Tyr204), ERK1/2, p16, p53, p21, mature TGF-β1, IL-11, and Snail. β-actin was used as the loading control. e Protein expression relative to β-actin was assessed by densitometric analysis. f Pulmonary AT2 cells were treated with TGF-β1 (5 ng/ml, 48 h), TGF-β1 (5 ng/ml, 48 h), and anti-IL-11 antibody (2 μg/ml, 48 h), IL-11 (5 ng/ml, 48 h), or IL-11 (5 ng/ml, 48 h) and the MEK inhibitor (PD98059) (10 μm, 48 h). Western blots for SFTPC, α-SMA, pERK1/2 (Thr202/Tyr204), ERK1/2, p16, p53, and p21. β-actin was used as the loading control. g Protein expression relative to β-actin was assessed by densitometric analysis. h Representative micrographs of cells immunofluorescently stained for α-SMA and SFTPC, with DAPI staining the nuclei. i The percentage of α-SMA- or SFTPC-positive areas was relative to the total. j WT AT2 cells treated with CM from third-passage pulmonary fibroblasts from the WT, Bmi-1−/−, Bmi-1−/−p16−/− or NAC-treated Bmi-1−/− (Bmi-1−/− + NAC) groups. k The percentage of α-SMA- or SFTPC-positive areas relative to the total. Six biological replicates were used per experiment. Values are the means ± SEM of six determinations. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01 compared with the Bmi-1−/−p16−/− group. ^P < 0.05, ^^P < 0.01, ^^^P < 0.001 compared with the vehicle group; +P < 0.05, ++P < 0.01, +++P < 0.001 compared with the TGF-β1 treatment group; @P < 0.05 compared with the TGF-β1 and anti-IL-11 antibody treatment group; −P < 0.05, −−P < 0.01 compared with the IL-11 treatment group.
Fig. 6 NAC treatment inhibited cell senescence, and TIME signaling mediated the EMT in Bmi-1−/− cells more than in Bmi-1−/−p16−/− AT2 cells. Pulmonary AT2 cells from 7-week-old WT, Bmi-1−/−, Bmi-1−/−p16−/−, and NAC-treated Bmi-1−/− (Bmi-1−/− + NAC) mice. a Representative micrographs of cells stained cytochemically for SA-β-gal. b Percentage of SA-β-gal-positive areas relative to the total. c Second-passage AT2 cell proliferation were determined by CCK-8 assays, and spectrophotometry at 450 nm. Cell number was determined at the indicated hours relative to the cell number at hour 0. d Western blots for SFTPC, α-SMA, pERK1/2 (Thr202/Tyr204), ERK1/2, p16, p53, p21, mature TGF-β1, IL-11, and Snail. β-actin was used as the loading control. e Protein expression relative to β-actin was assessed by densitometric analysis. f Pulmonary AT2 cells were treated with TGF-β1 (5 ng/ml, 48 h), TGF-β1 (5 ng/ml, 48 h), and anti-IL-11 antibody (2 μg/ml, 48 h), IL-11 (5 ng/ml, 48 h), or IL-11 (5 ng/ml, 48 h) and the MEK inhibitor (PD98059) (10 μm, 48 h). Western blots for SFTPC, α-SMA, pERK1/2 (Thr202/Tyr204), ERK1/2, p16, p53, and p21. β-actin was used as the loading control. g Protein expression relative to β-actin was assessed by densitometric analysis. h Representative micrographs of cells immunofluorescently stained for α-SMA and SFTPC, with DAPI staining the nuclei. i The percentage of α-SMA- or SFTPC-positive areas was relative to the total. j WT AT2 cells treated with CM from third-passage pulmonary fibroblasts from the WT, Bmi-1−/−, Bmi-1−/−p16−/− or NAC-treated Bmi-1−/− (Bmi-1−/− + NAC) groups. k The percentage of α-SMA- or SFTPC-positive areas relative to the total. Six biological replicates were used per experiment. Values are the means ± SEM of six determinations. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01 compared with the Bmi-1−/−p16−/− group. ^P < 0.05, ^^P < 0.01, ^^^P < 0.001 compared with the vehicle group; +P < 0.05, ++P < 0.01, +++P < 0.001 compared with the TGF-β1 treatment group; @P < 0.05 compared with the TGF-β1 and anti-IL-11 antibody treatment group; −P < 0.05, −−P < 0.01 compared with the IL-11 treatment group.CC BY · PubMed Central
Fig. 7 Inhibition of pERK1/2 (Thr202/Tyr204) translocation from the cytoplasm to the nucleus by p16 binding. a Pulmonary fibroblasts from WT mice were treated with TGF-β1 (5 ng/ml, 48 h), and cytoplasmic proteins were extracted for p16, Bmi-1, ERK1/2, or pERK1/2 (Thr202/Tyr204) coimmunoprecipitation. Western blots detecting ERK1/2, pERK1/2(Thr202/Tyr204) or p16. Pulmonary fibroblasts from Bmi-1−/− mice treated with TGF-β1 (5 ng/ml, 48 h) or vehicle. b Representative micrographs of Duolink proximity ligation assays (PLAs) for the interaction between p16 and ERK1/2 or p16 and pERK1/2 (Thr202/Tyr204), with DAPI staining the nuclei. PLA signal per cell relative to the vehicle. c Representative micrographs of cells immunofluorescently stained for p16 and ERK1/2 or p16 and pERK1/2 (Thr202/Tyr204), with DAPI staining the nuclei. d The percentage of areas positive for p16, ERK1/2, or pERK1/2 (Thr202/Tyr204) in the cytoplasm relative to the total. e Western blots of ERK1/2, pERK1/2 (Thr202/Tyr204), and p16 in the cytoplasm and pERK1/2 (Thr202/Tyr204) in the nucleus of pulmonary fibroblasts from WT and Bmi-1−/− mice treated with vehicle or TGF-β1. f Protein expression relative to β-actin in the cytoplasm and histone H3 in the nucleus was assessed by densitometric analysis. Three biological replicates were used per experiment. Values are the means ± SEM of six determinations. **P < 0.01, ***P < 0.001 compared with the vehicle-treated WT (Vehicle + WT) group; ##P < 0.01, ###P < 0.001 compared with the TGF-β1-treated WT (TGF-β1 + WT) group; &P < 0.05, &&P < 0.01, &&&P < 0.001 compared with the vehicle-treated Bmi-1−/− (Vehicle + Bmi-1−/−) group.
Fig. 7 Inhibition of pERK1/2 (Thr202/Tyr204) translocation from the cytoplasm to the nucleus by p16 binding. a Pulmonary fibroblasts from WT mice were treated with TGF-β1 (5 ng/ml, 48 h), and cytoplasmic proteins were extracted for p16, Bmi-1, ERK1/2, or pERK1/2 (Thr202/Tyr204) coimmunoprecipitation. Western blots detecting ERK1/2, pERK1/2(Thr202/Tyr204) or p16. Pulmonary fibroblasts from Bmi-1−/− mice treated with TGF-β1 (5 ng/ml, 48 h) or vehicle. b Representative micrographs of Duolink proximity ligation assays (PLAs) for the interaction between p16 and ERK1/2 or p16 and pERK1/2 (Thr202/Tyr204), with DAPI staining the nuclei. PLA signal per cell relative to the vehicle. c Representative micrographs of cells immunofluorescently stained for p16 and ERK1/2 or p16 and pERK1/2 (Thr202/Tyr204), with DAPI staining the nuclei. d The percentage of areas positive for p16, ERK1/2, or pERK1/2 (Thr202/Tyr204) in the cytoplasm relative to the total. e Western blots of ERK1/2, pERK1/2 (Thr202/Tyr204), and p16 in the cytoplasm and pERK1/2 (Thr202/Tyr204) in the nucleus of pulmonary fibroblasts from WT and Bmi-1−/− mice treated with vehicle or TGF-β1. f Protein expression relative to β-actin in the cytoplasm and histone H3 in the nucleus was assessed by densitometric analysis. Three biological replicates were used per experiment. Values are the means ± SEM of six determinations. **P < 0.01, ***P < 0.001 compared with the vehicle-treated WT (Vehicle + WT) group; ##P < 0.01, ###P < 0.001 compared with the TGF-β1-treated WT (TGF-β1 + WT) group; &P < 0.05, &&P < 0.01, &&&P < 0.001 compared with the vehicle-treated Bmi-1−/− (Vehicle + Bmi-1−/−) group.CC BY · PubMed Central
Fig. 8 P16 deletion or downregulation promoted translocation of pERK1/2 (Thr202/Tyr204) from the cytoplasm to the nucleus. a Western blots of p16, pERK1/2 (Thr202/Tyr204), and ERK1/2 in the cytoplasm and p16 and pERK1/2 (Thr202/Tyr204) in the nucleus of fibroblasts from WT, Bmi-1−/−, Bmi-1−/−p16−/−, or NAC-treated Bmi-1−/− (Bmi-1−/− + NAC) mice. b Protein expression relative to β-actin in the cytoplasm and histone H3 in the nucleus was assessed by densitometric analysis. c pERK1/2 (Thr202/Tyr204) protein levels relative to total pERK1/2 (Thr202/Tyr204) protein levels in the cytoplasm and nucleus. Three biological replicates were used per experiment. Values are the means ± SEM of six determinations. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01, &&&P < 0.001 compared with the Bmi-1−/−p16−/− group. d Graphical Abstract In Bmi-1 null mice, upregulated TGF-β1/IL-11/MEK/ERK (TIME) signaling contributed to senescence-associated pulmonary fibrosis (SAPF) and dysfunction by promoting cell senescence and stimulating TGF-β1 and IL-11 secretion and collagen 1 production in aging pulmonary fibroblasts and the epithelial-to-mesenchymal transition (EMT) in aging alveolar type II epithelial cells. NAC treatment ameliorated pulmonary dysfunction and SAPF by downregulating TIME signaling more than that of p16 deletion by inhibiting oxidative stress and DNA damage and promoting ubiquitin-proteasome degradation of p16 and p53.
Fig. 8 P16 deletion or downregulation promoted translocation of pERK1/2 (Thr202/Tyr204) from the cytoplasm to the nucleus. a Western blots of p16, pERK1/2 (Thr202/Tyr204), and ERK1/2 in the cytoplasm and p16 and pERK1/2 (Thr202/Tyr204) in the nucleus of fibroblasts from WT, Bmi-1−/−, Bmi-1−/−p16−/−, or NAC-treated Bmi-1−/− (Bmi-1−/− + NAC) mice. b Protein expression relative to β-actin in the cytoplasm and histone H3 in the nucleus was assessed by densitometric analysis. c pERK1/2 (Thr202/Tyr204) protein levels relative to total pERK1/2 (Thr202/Tyr204) protein levels in the cytoplasm and nucleus. Three biological replicates were used per experiment. Values are the means ± SEM of six determinations. *P < 0.05, **P < 0.01, ***P < 0.001 compared with the WT group; #P < 0.05, ##P < 0.01, ###P < 0.001 compared with the Bmi-1−/− group; &P < 0.05, &&P < 0.01, &&&P < 0.001 compared with the Bmi-1−/−p16−/− group. d Graphical Abstract In Bmi-1 null mice, upregulated TGF-β1/IL-11/MEK/ERK (TIME) signaling contributed to senescence-associated pulmonary fibrosis (SAPF) and dysfunction by promoting cell senescence and stimulating TGF-β1 and IL-11 secretion and collagen 1 production in aging pulmonary fibroblasts and the epithelial-to-mesenchymal transition (EMT) in aging alveolar type II epithelial cells. NAC treatment ameliorated pulmonary dysfunction and SAPF by downregulating TIME signaling more than that of p16 deletion by inhibiting oxidative stress and DNA damage and promoting ubiquitin-proteasome degradation of p16 and p53.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

3 retracted

Show all 48 references

Cited by

See all 151

Metadata

Authors
Chen, H., Chen, H., Liang, J., Gu, X., Zhou, J., Xie, C., Lv, X., Wang, R., Li, Q., Mao, Z., Sun, H., Zuo, G., Miao, D., & Jin, J.
Affiliations
  • State Key Laboratory of Reproductive Medicine (CN)
  • Nanjing Medical University (CN)
Corresponding author
Jin, Jianliang
Venue
Experimental & Molecular Medicine
Published
2020-01
Volume
52
Issue
1
Pages
130-151
ISSN
  • 1226-3613 (ISSN-L)
  • 2092-6413
OpenAlex
W2998862756
Cited by
149
References
48
Citations by year
2026: 16 · 2025: 30 · 2024: 24 · 2023: 32 · 2022: 28 · 2021: 11 · 2020: 7
FWCI
11.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Experimental & Molecular Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81730066, 81871097, 81230009, 81571371)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
premature senescence, p16INK4a, reactive oxygen species, N-acetylcysteine, oxidative stress, DNA damage, senescence-associated secretory phenotype, epithelial-mesenchymal transition, alveolar type II cells, lung fibroblasts, collagen deposition
MeSH terms
Animals, Cells, Cultured, Disease Models, Animal, DNA Damage, Fibroblasts, Fibrosis, Humans, Lung, Proto-Oncogene Proteins, Signal Transduction, Cellular Senescence, Interleukin-11, Oxidative Stress, Mitogen-Activated Protein Kinase Kinases, Ubiquitin, Proteasome Endopeptidase Complex, Mice, Transforming Growth Factor beta1, Polycomb Repressive Complex 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency. https://app.cochat.ai/papers/10.1038/s12276-019-0371-7
The paper
Chen, H., Chen, H., Liang, J., Gu, X., Zhou, J., Xie, C., Lv, X., Wang, R., Li, Q., Mao, Z., Sun, H., Zuo, G., Miao, D., & Jin, J. (2020). TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency. Experimental & Molecular Medicine. https://doi.org/10.1038/s12276-019-0371-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.